Developer docs
API playgroundTry for free, no card

Search company profiles

Prozomix

Full company profile

uuid00097zy

Namestring
Prozomix
Legal namestring
Prozomix Limited
Websiteurl
prozomix.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Prozomix is a UK-based biotechnology company founded in 2008 that discovers, develops, and manufactures a large catalogue of novel biocatalysis enzymes for pharmaceutical and industrial customers. The company operates a vertically integrated model combining proprietary metagenomic enzyme discovery (GRASP™ and meta-GRASP technologies) with in-house fermentation manufacturing at its Haltwhistle, Northumberland site, spanning a Flask Lab (200 enzymes/day), a 750 L Pilot Plant (operational since 2017), and a new Production Plant with three 2400 L vessels nearing full operation in mid-2024. Over a decade of environmental sampling at more than 400 UK locations — including a 2023 UK coastline circumnavigation — has generated trillions of base pairs of sequence data and a proprietary catalogue of more than 6,000 native enzymes across 50+ panels (KREDs, IREDs, transaminases, EREDs, P450s, nitrilases, and others).

The company's commercial model rests on four streams: (1) free-to-screen Biocatalysis Enzyme Toolkit driving adoption, with paid enzyme catalogue sales at commoditised global list prices (e.g., $340 per 1 g to $165,000 per 100 kg); (2) contract manufacturing services for small-scale (0.1 g to hundreds of grams, 7-day turnaround) and bulk-scale (1 kg to 100 kg) production; (3) AI-enabled Gen2/NextGen enzyme optimisation via a partnership with Ginkgo Bioworks, monetising accumulated customer screening data; and (4) the Commercial Academic Partner (CAP) Programme and Literature Enzyme Service, which commercialise academic enzymes and pay 17.5% and 10% royalties respectively. Customers include 17 of the top 20 global pharmaceutical companies, with distribution via direct e-commerce, an exclusive Japan distributor (Meiji Seika Pharma since 2012), and a March 2026 strategic partnership with CDMO SK pharmteco for U.S./Europe/Asia market access. The company is privately held, founder-controlled since inception with no external equity funding rounds recorded, and operates within 11–50 employees.

Short descriptiontext

Prozomix is a UK biotechnology company that discovers and manufactures a proprietary catalogue of more than 6,000 metagenomic biocatalysis enzymes across 50+ panels, serving 17 of the top 20 global pharmaceutical companies via a free-to-screen Biocatalysis Enzyme Toolkit, commoditised catalogue sales, and small- to bulk-scale contract manufacturing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHaltwhistle, United Kingdom
HQ citystring
Haltwhistle
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biocatalysis enzymes, enzyme screening kits, metagenomic enzyme discovery, contract enzyme manufacturing, pharmaceutical biocatalysis
Industry2 codes
PRIMARYEUAAAIAL
Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Other Basic Organic Chemical Manufacturing32519
Product category
Biocatalysis Enzymes / Industrial Biocatalysts
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Enzyme Product Sales
TypeOne Time License
Description

Prozomix sells its catalogue of over 6,000 biocatalyst enzymes at commoditised global list prices. Customers purchase enzyme hits at any scale (from 100 mg to 100 kg) at known, fixed prices. The model is transaction-based, with volume-based pricing tiers. Pricing is standardised globally with no negotiation required.

prozomix.com
2Contract Manufacturing (CMO) Services
TypeProfessional Services
Description

Prozomix provides fee-for-service contract manufacturing of enzymes at small scale (0.1 g to 100s g via the Flask Lab) and bulk scale (1 kg to 100 kg via its Pilot and Production Plants). The company also offers custom CMO services where customers supply their own expression plasmids and Prozomix produces enzyme panels within 7 working days.

prozomix.com
3Commercial Academic Partner (CAP) Programme
TypeLicensing Royalties
Description

Prozomix commercialises academic plasmids encoding recombinant enzymes through its CAP Programme, paying a 17.5% royalty on all sales to the academic contributor. Academic enzymes are made available on Prozomix's shelf, with a 10% gross sales royalty paid to the originating academic.

prozomix.com
4AI Enzyme Optimisation Services
TypeProfessional Services
Description

In collaboration with Ginkgo Bioworks, Prozomix offers second generation (Gen2) and next generation (NextGen) AI-powered enzyme solutions derived from customers' historical and new Biocatalysis Enzyme Toolkit screening data, enabling optimisation of biocatalysts for demanding applications.

prozomix.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Supply Chain, Operations, Marketing or Sales
Pricing details5 tiers
1Standard enzyme pricing — commodity crude lyophilised powder
ModelUnit PricingBilling cadencePay-as-you-go
Notes

100 mg free-of-charge to Toolkit users. 1 g = $340; 10 g = $575; 100 g = $3,850; 1 kg = $17,050; 10 kg = $55,000; 100 kg = $165,000. Prices are fixed globally, tied to USA Retail Price Index since 2015.

prozomix.com
2AI Enzyme / Optimised Variant Pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Customers who obtain optimised variants through the free Prozomix Promise improvement service purchase new enzymes at standard list prices: 100 mg free-of-charge samples; 1 g = $340; 10 g = $575; 100 g = $3,850; 1 kg = $17,050; 10 kg = $55,000; 100 kg = $165,000.

prozomix.com
3Enzyme Cofactors
ModelUnit PricingBilling cadencePay-as-you-go
Notes

PRO-NAD: $19.50/g; PRO-NADH: $37.50/g; PRO-NADP: $20.00/g; PRO-NADPH: $40.00/g. Available in quantities from 0.11 g to 1 kg depending on product.

prozomix.com
4Free Biocatalysis Enzyme Toolkit
ModelFreemiumBilling cadencePay-as-you-go
Notes

The Biocatalysis Enzyme Toolkit — comprising over 50 panels of enzymes totalling more than 6,000 native enzymes — is provided completely free-of-charge (including shipping) to customers who sign a Prozomix Evaluation Agreement, Enzyme Supply Agreement, or Enzyme Discovery and Supply Agreement.

prozomix.com
5CoEBio3 Consortium Products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CoEBio3 P450 Collection: $165.00 per 96 Well Screening Plate (1 mg each enzyme per well), or 1 g each / 10 g each. CoEBio3 R-AMO Collection: $165.00 per 96 Well Screening Plate. These are commercial consortium products available at fixed prices.

prozomix.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Biocatalysis Enzyme Toolkit
Description

Free-to-use enzyme screening toolkit offering maximum diversity proprietary biocatalysts

prozomix.com
+2 more records
Core offering1 text field

Prozomix discovers, manufactures, and supplies highly purified novel enzymes (biocatalysts) for pharmaceutical and industrial biocatalysis. It offers the free Biocatalysis Enzyme Toolkit — over 6,000 native enzymes across 50+ panels — for screening, with hits then purchased at commoditised global prices from 100 mg to 100 kg. The company also provides small-scale and bulk contract manufacturing (CMO) services, AI-optimised Gen2/NextGen enzymes via Ginkgo Bioworks, and academic commercialisation programmes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 17 of the top 20 global pharmaceutical companies use Prozomix
+6 more records
Product overview1 text field

Prozomix is a UK-based biotechnology company that has developed the largest range of natural maximum-diversity proprietary biocatalysts available via a free-to-use Biocatalysis Enzyme Toolkit. The core offering consists of over 6000 novel enzymes across 50+ distinct enzyme panels (including KREDs with 762 enzymes, IREDs with 500+ enzymes, Transaminases with 480 enzymes, EREDs with 120 enzymes, P450s, Nitrilases, Nitroreductases, and more), all discoverable through free screening before scale-up purchases. The portfolio spans enzyme kits for initial discovery, individual enzyme products from the catalogue, cofactor recycling enzymes and cofactors, AI-enabled enzyme optimization through Ginkgo Bioworks collaboration (Gen2/Nextgen), and comprehensive contract manufacturing services from small-scale (grams) to bulk production (100kg). Additional services include hit improvement programs, academic partnership opportunities, and literature enzyme availability. The company operates from its Haltwhistle, Northumberland facility with in-house R&D, production, and proprietary GRASP™ genome-mining technology.

Product and service21 records
1Biocatalysis Enzyme Toolkit
CategoryBiocatalysis Enzyme Platform
Description

Free-to-use discovery platform comprising over 6,000 native enzymes across 50+ panels (KREDs, IREDs, Transaminases, EREDs, P450s, Nitrilases, Nitroreductases, 2-OG Hydroxylases, Epoxide Hydrolases, Carboxylesterases), enabling pharmaceutical, CDMO, and industrial customers to screen maximum-diversity biocatalysts for novel applications including API synthesis, flavours, fragrances, food and health. Hits are then purchased at any scale from 100 mg to 100 kg at known commoditised prices.

2Ketoreductase (KRED) Screening Kit
CategoryEnzyme Screening Kit
Description

Screening kit of 762 diverse wild-type ketoreductase enzymes spanning 8 × 96-well screening plates, also available in colorimetric KREDy-to-Go format, designed for biocatalytic ketone reduction in pharmaceutical and industrial applications.

3Imine Reductase (IRED) Screening Kit
CategoryEnzyme Screening Kit
Description

Screening kit of over 500 novel imine reductase enzymes (expanding to 762) across 5 screening plates, developed from Prozomix's proprietary metagenomics platform for reductive amination and chiral amine synthesis.

4Transaminase Screening Kit
CategoryEnzyme Screening Kit
Description

Screening kit of 480 novel wild-type transaminase enzymes across 5 screening plates, including a Class IV Transaminase plate, sourced from UK biodiversity for amine synthesis applications.

5Ene-Reductase (ERED) Screening Kit
CategoryEnzyme Screening Kit
Description

Screening kit of 120 novel wild-type ene-reductase enzymes covering both FMN- and non-flavin EREDs, with expansion to 384 EREDs targeted by Q4 2024 for C=C bond reduction applications.

6Cytochrome P450 Screening Kit
CategoryEnzyme Screening Kit
Description

Screening kit of 48 characterised novel cytochrome P450 enzymes, predominantly self-sufficient P450s from Class VII (P450RhF-like) and Class VIII (P450BM3-like) classes, for selective oxidation reactions.

7Nitrilase Screening Kit
CategoryEnzyme Screening Kit
Description

Screening kit of 96 diverse wild-type nitrilase enzymes available in both vial and plate format for nitrile hydrolysis and carboxylic acid synthesis applications.

8Nitroreductase Screening Kit
CategoryEnzyme Screening Kit
Description

Screening kit of 160 novel nitroreductase enzymes expanded from an initial 66-enzyme panel designed during the EU H2020 Metafluidics project, for nitro-group reduction applications.

92-OG Hydroxylase Screening Kit
CategoryEnzyme Screening Kit
Description

Screening kit of 70 diverse 2-oxoglutarate-dependent hydroxylase enzymes designed from metagenomic libraries, with 50+ literature enzymes also available for C–H hydroxylation applications.

10Epoxide Hydrolase Screening Kit
CategoryEnzyme Screening Kit
Description

Screening kit of 96 diverse wild-type epoxide hydrolase enzymes from both the αβ-hydrolase family and limonene EHs, available in vial and plate format for epoxide hydrolysis applications.

11Carboxylesterase Screening Kit
CategoryEnzyme Screening Kit
Description

Screening kit of 60 carboxylesterase enzymes in vial and plate format, expanding toward 96 enzymes by Q3 2024, for ester hydrolysis and related applications.

12Cofactor Recycling Enzymes
CategoryEnzyme Product Line
Description

Line of 8 cofactor recycling enzymes including formate dehydrogenases (FDH) and glucose dehydrogenases (GDH) for NAD(P)H regeneration in biocatalytic processes.

13Enzyme Cofactors
CategoryChemical Product Line
Description

PRO-NAD, PRO-NADH, PRO-NADP, and PRO-NADPH cofactor products for biocatalysis reactions, available in quantities from 0.11 g to 1 kg at unit prices such as PRO-NAD at $19.50/g and PRO-NADPH at $40.00/g.

14AI Enzymes (Gen2/NextGen)
CategoryAI-enabled Biocatalyst Product
Description

Second-generation and next-generation AI-optimised enzyme solutions developed in collaboration with Ginkgo Bioworks, leveraging customer screening data from the Biocatalysis Enzyme Toolkit for superior biocatalyst performance in demanding applications.

15Small-Scale CMO Service
CategoryContract Manufacturing Service
Description

Fee-for-service contract manufacturing of enzymes from 0.1 g to 100s of grams with 7-day turnaround from plasmid arrival, utilising 200 enzymes/day Flask Lab capacity and including custom CMO where customers supply their own expression plasmids.

16Bulk CMO Service
CategoryContract Manufacturing Service
Description

Fee-for-service large-scale enzyme manufacturing from 1 kg to 100 kg using Prozomix's 750 L Pilot Plant and 3 × 2400 L Production Plant (6,000 L total), with fixed commoditised pricing and long-term dedicated LOT storage.

17Prozomix Promise (Hit Improvement Service)
CategoryEnzyme Optimisation Service
Description

Free-of-charge biocatalyst hit improvement service selecting 12–24 homologues from Prozomix's proprietary metagenomic database to optimise enzyme activity, selectivity, or stability; customers with an existing enzyme hit that is not good enough receive homologues synthesised, cloned, and produced free-of-charge for screening.

18Commercial Academic Partner (CAP) Programme
CategoryAcademic Partnership Programme
Description

Academic partnership programme enabling rapid commercialisation of recombinant enzymes with a 17.5% royalty paid to the academic contributor on all sales, achieving commercialisation within approximately 3 months.

19Literature Enzyme Request Service
CategoryEnzyme Service
Description

Service that makes published biocatalysts available as off-the-shelf products, paying a 10% gross sales royalty to originating academics and providing 2–4 week delivery for new requests.

20Immobilised Enzymes (via CLEA Technologies collaboration)
CategoryCollaboration Product
Description

Custom enzyme immobilisation services for Prozomix enzymes (KREDs, EREDs, P450s, nitrilases) provided through collaboration with CLEA Technologies B.V., combining GRASP™ biocatalyst development with CLEA's advanced immobilisation technology.

21CoEBio3 Consortium Products
CategoryConsortium Enzyme Collection
Description

Commercial consortium products including the CoEBio3 P450 Collection and CoEBio3 R-AMO (R-Selective Amine Oxidases) Collection, developed through the Centre of Excellence for Biocatalysis, available at $165.00 per 96-well screening plate (1 mg each enzyme per well).

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

SK pharmteco, a global contract development and manufacturing organization (CDMO), and Prozomix announced a strategic partnership to integrate Prozomix's biocatalyst libraries into SK pharmteco's small-molecule development and manufacturing services. SK pharmteco gains access to over 6,000 diverse native biocatalysts for use across its R&D centers in the U.S., Europe, and Asia, enabling rapid identification of high-performing enzymes for complex active pharmaceutical ingredient synthesis. The partnership aims to accelerate the transition to more sustainable, efficient, and cost-effective pharmaceutical manufacturing processes for clients globally.

2Meiji Seika Pharma Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2012-04-02
Description

Meiji Seika Pharma Co., LTD. was appointed as Prozomix's exclusive distributor in Japan in April 2012. Meiji hosts a Japanese version of the Prozomix enzyme catalogue on its website, ensuring both good web visibility and efficient customer experience locally in Japan. With their fundamental and applied knowledge of enzyme technology and industrial enzyme capability, this collaboration is an important milestone in Prozomix's global marketing strategy.

prozomix.com
Strategic tierCoreTypeTechnology or Integration
Description

Prozomix collaborates with Ginkgo Bioworks to leverage customer screening data from the Biocatalysis Enzyme Toolkit, enabling the development of second generation (Gen2) and next generation (NextGen) AI-powered enzyme solutions. Customers can leverage their historical and new Prozomix screening data in collaboration with Ginkgo to unlock unrivalled AI enzyme solutions for demanding applications.

4KYROBIO Consortium (EU FP7-KBBE Programme)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

As part of a 17-strong academic/commercial EU consortium, Prozomix participated in the €7.8M KYROBIO Project (Grant No. 289646) under the FP7-KBBE Programme, aimed at discovering, developing, and demonstrating biocatalysts for industrial synthesis of chiral chemicals. The consortium included BICT, Ingenza, CLEA Technologies, BioInfoBank Institute, VTU Technology, ACIB, University of Graz, X-Zyme, evocatal, Bio-prodict, University of Manchester, CIKTN, C-Tech Innovation, University of Groningen, University of Stuttgart, and Technical University of Denmark. Prozomix's role was discovery, development, and commercialisation of novel nitrile hydratase biocatalysts.

prozomix.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

As part of a 14-strong academic/commercial EU consortium, Prozomix was awarded a Horizon Europe research grant (Project Grant No. 101081957) focused on 'Safely and sustainably utilising marine microbiomes'. Over a 4-year period, Prozomix is using its advanced enzyme capabilities to discover, develop, and commercialise novel biocatalysts from UK marine biodiversity, expanding its collection of Biocatalysis enzymes with new members becoming commercially available through the Biocatalysis Enzyme Toolkit.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Northumbria University and Prozomix have collaborated on multiple research projects including a BBSRC iCASE Award (2015) focused on novel biocatalytic routes towards volatile sulphur compounds, and a TSB Grant for sustainable flavour compound production from vegetable oil waste streams.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Amano Enzyme
TypeBroad incumbent
Description

Amano Enzyme is a Japanese specialty enzyme manufacturer with a long-established presence in food, pharmaceutical, and diagnostic enzymes. It is comparable as a broad incumbent in the global enzyme market, with a similar global distribution model and a Japanese home market presence.

TypeEmerging player
Description

Arzeda combines computational protein design with synthetic biology to create novel enzymes for industrial applications. It is comparable as an emerging player in enzyme engineering, taking a competing AI-first approach to the same pharma and industrial customers.

TypeBroad incumbent
Description

Biosynth (formerly Biosynth Carbosynth) is a large specialty chemicals and life sciences supplier with a growing enzyme and biocatalysis portfolio. It is comparable as a broad incumbent that supplies life science tools and specialty enzymes to pharmaceutical and academic customers globally.

TypeBroad incumbent
Description

Novonesis is the world's largest industrial enzyme company, offering a broad portfolio across food, beverage, agriculture, and pharma. While not specialising in pharma API biocatalysis, its scale and R&D resources make it a broad incumbent whose moves into biocatalysis could threaten niche players like Prozomix.

5AB Enzymes (Associated British Foods)
TypeBroad incumbent
Description

AB Enzymes is an established industrial enzyme manufacturer with a broad product portfolio in food, baking, and brewing. It serves as a broad incumbent comparable in the enzyme industry, with significant manufacturing scale and customer relationships.

TypeEmerging player
Description

EnginZyme is a Swedish company developing immobilised enzyme technology for chemical manufacturing. It is comparable as an emerging player in industrial biocatalysis with overlapping pharma and industrial customer use cases, though its focus is on immobilisation rather than enzyme discovery.

TypeDirect peer
Description

Codexis is a leading enzyme engineering company focused on biocatalysts for pharmaceutical manufacturing, serving the same big-pharma customer base with both native and engineered enzymes. It is the most direct competitor to Prozomix's Biocatalysis Enzyme Toolkit and CMO services.

TypeDirect peer
Description

c-LEcta is a German biocatalysis company developing and commercialising engineered enzymes for pharma, food, and industrial applications, now part of Kerry Group. It directly competes with Prozomix in supplying specialty biocatalysts to pharmaceutical manufacturers.

TypeEmerging player
Description

Bota Bio is a synthetic biology company developing engineered enzymes and microbes for sustainable chemical and material production. It is comparable as an emerging player in AI-driven enzyme engineering for industrial applications, with overlapping pharmaceutical and specialty chemical customers.

10Evocatal (acquired by BASF)
TypeDirect peer
Description

Evocatal was a German specialty enzyme company focused on biocatalysis for industrial applications, with a comparable product portfolio in oxidoreductases, transaminases, and hydrolases. Acquired by BASF, it represents a direct competitive comparable in the biocatalyst space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prozomix

Biocatalysis Enzymes / Industrial Biocatalystsprozomix.com

Prozomix is a UK biotechnology company that discovers and manufactures a proprietary catalogue of more than 6,000 metagenomic biocatalysis enzymes across 50+ panels, serving 17 of the top 20 global pharmaceutical companies via a free-to-screen Biocatalysis Enzyme Toolkit, commoditised catalogue sales, and small- to bulk-scale contract manufacturing.

What Prozomix does

Prozomix is a UK-based biotechnology company founded in 2008 that discovers, develops, and manufactures a large catalogue of novel biocatalysis enzymes for pharmaceutical and industrial customers. The company operates a vertically integrated model combining proprietary metagenomic enzyme discovery (GRASP™ and meta-GRASP technologies) with in-house fermentation manufacturing at its Haltwhistle, Northumberland site, spanning a Flask Lab (200 enzymes/day), a 750 L Pilot Plant (operational since 2017), and a new Production Plant with three 2400 L vessels nearing full operation in mid-2024. Over a decade of environmental sampling at more than 400 UK locations — including a 2023 UK coastline circumnavigation — has generated trillions of base pairs of sequence data and a proprietary catalogue of more than 6,000 native enzymes across 50+ panels (KREDs, IREDs, transaminases, EREDs, P450s, nitrilases, and others).

The company's commercial model rests on four streams: (1) free-to-screen Biocatalysis Enzyme Toolkit driving adoption, with paid enzyme catalogue sales at commoditised global list prices (e.g., $340 per 1 g to $165,000 per 100 kg); (2) contract manufacturing services for small-scale (0.1 g to hundreds of grams, 7-day turnaround) and bulk-scale (1 kg to 100 kg) production; (3) AI-enabled Gen2/NextGen enzyme optimisation via a partnership with Ginkgo Bioworks, monetising accumulated customer screening data; and (4) the Commercial Academic Partner (CAP) Programme and Literature Enzyme Service, which commercialise academic enzymes and pay 17.5% and 10% royalties respectively. Customers include 17 of the top 20 global pharmaceutical companies, with distribution via direct e-commerce, an exclusive Japan distributor (Meiji Seika Pharma since 2012), and a March 2026 strategic partnership with CDMO SK pharmteco for U.S./Europe/Asia market access. The company is privately held, founder-controlled since inception with no external equity funding rounds recorded, and operates within 11–50 employees.

Prozomix firmographics

Firmographics
Name
Prozomix
Legal name
Prozomix Limited
Website
https://prozomix.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Prozomix is a UK biotechnology company that discovers and manufactures a proprietary catalogue of more than 6,000 metagenomic biocatalysis enzymes across 50+ panels, serving 17 of the top 20 global pharmaceutical companies via a free-to-screen Biocatalysis Enzyme Toolkit, commoditised catalogue sales, and small- to bulk-scale contract manufacturing.
Ownership category
akta.pro rank

Prozomix industry classification

Industry
Product category
Biocatalysis Enzymes / Industrial Biocatalysts
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Basic Organic Chemical Manufacturing (32519)
akta.pro industry
PRIMARYEUAAAIAL
Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Biocatalysis enzymes
  • Enzyme screening kits
  • Metagenomic enzyme discovery
  • Contract enzyme manufacturing
  • Pharmaceutical biocatalysis

Where Prozomix is headquartered

Location

Headquarters

HQ city
Haltwhistle
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Prozomix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Infrastructure, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Enzyme Product Sales: Prozomix sells its catalogue of over 6,000 biocatalyst enzymes at commoditised global list prices. Customers purchase enzyme hits at any scale (from 100 mg to 100 kg) at known, fixed prices. The model is transaction-based, with volume-based pricing tiers. Pricing is standardised globally with no negotiation required.
  2. Contract Manufacturing (CMO) Services: Prozomix provides fee-for-service contract manufacturing of enzymes at small scale (0.1 g to 100s g via the Flask Lab) and bulk scale (1 kg to 100 kg via its Pilot and Production Plants). The company also offers custom CMO services where customers supply their own expression plasmids and Prozomix produces enzyme panels within 7 working days.
  3. Commercial Academic Partner (CAP) Programme: Prozomix commercialises academic plasmids encoding recombinant enzymes through its CAP Programme, paying a 17.5% royalty on all sales to the academic contributor. Academic enzymes are made available on Prozomix's shelf, with a 10% gross sales royalty paid to the originating academic.
  4. AI Enzyme Optimisation Services: In collaboration with Ginkgo Bioworks, Prozomix offers second generation (Gen2) and next generation (NextGen) AI-powered enzyme solutions derived from customers' historical and new Biocatalysis Enzyme Toolkit screening data, enabling optimisation of biocatalysts for demanding applications.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard enzyme pricing — commodity crude lyophilised powder
Unit PricingPay-as-you-goAI Enzyme / Optimised Variant Pricing
Unit PricingPay-as-you-goEnzyme Cofactors
FreemiumPay-as-you-goFree Biocatalysis Enzyme Toolkit
Unit PricingPay-as-you-goCoEBio3 Consortium Products

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Prozomix product offering

Product offering

Core offering

Prozomix discovers, manufactures, and supplies highly purified novel enzymes (biocatalysts) for pharmaceutical and industrial biocatalysis. It offers the free Biocatalysis Enzyme Toolkit — over 6,000 native enzymes across 50+ panels — for screening, with hits then purchased at commoditised global prices from 100 mg to 100 kg. The company also provides small-scale and bulk contract manufacturing (CMO) services, AI-optimised Gen2/NextGen enzymes via Ginkgo Bioworks, and academic commercialisation programmes.

Product overview

Prozomix is a UK-based biotechnology company that has developed the largest range of natural maximum-diversity proprietary biocatalysts available via a free-to-use Biocatalysis Enzyme Toolkit. The core offering consists of over 6000 novel enzymes across 50+ distinct enzyme panels (including KREDs with 762 enzymes, IREDs with 500+ enzymes, Transaminases with 480 enzymes, EREDs with 120 enzymes, P450s, Nitrilases, Nitroreductases, and more), all discoverable through free screening before scale-up purchases. The portfolio spans enzyme kits for initial discovery, individual enzyme products from the catalogue, cofactor recycling enzymes and cofactors, AI-enabled enzyme optimization through Ginkgo Bioworks collaboration (Gen2/Nextgen), and comprehensive contract manufacturing services from small-scale (grams) to bulk production (100kg). Additional services include hit improvement programs, academic partnership opportunities, and literature enzyme availability. The company operates from its Haltwhistle, Northumberland facility with in-house R&D, production, and proprietary GRASP™ genome-mining technology.

Differentiator

Problem solved

Functional benefit

Brands

  • Biocatalysis Enzyme Toolkit: Free-to-use enzyme screening toolkit offering maximum diversity proprietary biocatalysts
  • GRASP™
  • meta-GRASP

Products and services

  • Biocatalysis Enzyme Toolkit Free-to-use discovery platform comprising over 6,000 native enzymes across 50+ panels (KREDs, IREDs, Transaminases, EREDs, P450s, Nitrilases, Nitroreductases, 2-OG Hydroxylases, Epoxide Hydrolases, Carboxylesterases), enabling pharmaceutical, CDMO, and industrial customers to screen maximum-diversity biocatalysts for novel applications including API synthesis, flavours, fragrances, food and health. Hits are then purchased at any scale from 100 mg to 100 kg at known commoditised prices.
  • Ketoreductase (KRED) Screening Kit Screening kit of 762 diverse wild-type ketoreductase enzymes spanning 8 × 96-well screening plates, also available in colorimetric KREDy-to-Go format, designed for biocatalytic ketone reduction in pharmaceutical and industrial applications.
  • Imine Reductase (IRED) Screening Kit Screening kit of over 500 novel imine reductase enzymes (expanding to 762) across 5 screening plates, developed from Prozomix's proprietary metagenomics platform for reductive amination and chiral amine synthesis.
  • Transaminase Screening Kit Screening kit of 480 novel wild-type transaminase enzymes across 5 screening plates, including a Class IV Transaminase plate, sourced from UK biodiversity for amine synthesis applications.
  • Ene-Reductase (ERED) Screening Kit Screening kit of 120 novel wild-type ene-reductase enzymes covering both FMN- and non-flavin EREDs, with expansion to 384 EREDs targeted by Q4 2024 for C=C bond reduction applications.
  • Cytochrome P450 Screening Kit Screening kit of 48 characterised novel cytochrome P450 enzymes, predominantly self-sufficient P450s from Class VII (P450RhF-like) and Class VIII (P450BM3-like) classes, for selective oxidation reactions.
  • Nitrilase Screening Kit Screening kit of 96 diverse wild-type nitrilase enzymes available in both vial and plate format for nitrile hydrolysis and carboxylic acid synthesis applications.
  • Nitroreductase Screening Kit Screening kit of 160 novel nitroreductase enzymes expanded from an initial 66-enzyme panel designed during the EU H2020 Metafluidics project, for nitro-group reduction applications.
  • 2-OG Hydroxylase Screening Kit Screening kit of 70 diverse 2-oxoglutarate-dependent hydroxylase enzymes designed from metagenomic libraries, with 50+ literature enzymes also available for C–H hydroxylation applications.
  • Epoxide Hydrolase Screening Kit Screening kit of 96 diverse wild-type epoxide hydrolase enzymes from both the αβ-hydrolase family and limonene EHs, available in vial and plate format for epoxide hydrolysis applications.
  • Carboxylesterase Screening Kit Screening kit of 60 carboxylesterase enzymes in vial and plate format, expanding toward 96 enzymes by Q3 2024, for ester hydrolysis and related applications.
  • Cofactor Recycling Enzymes Line of 8 cofactor recycling enzymes including formate dehydrogenases (FDH) and glucose dehydrogenases (GDH) for NAD(P)H regeneration in biocatalytic processes.
  • Enzyme Cofactors PRO-NAD, PRO-NADH, PRO-NADP, and PRO-NADPH cofactor products for biocatalysis reactions, available in quantities from 0.11 g to 1 kg at unit prices such as PRO-NAD at $19.50/g and PRO-NADPH at $40.00/g.
  • AI Enzymes (Gen2/NextGen) Second-generation and next-generation AI-optimised enzyme solutions developed in collaboration with Ginkgo Bioworks, leveraging customer screening data from the Biocatalysis Enzyme Toolkit for superior biocatalyst performance in demanding applications.
  • Small-Scale CMO Service Fee-for-service contract manufacturing of enzymes from 0.1 g to 100s of grams with 7-day turnaround from plasmid arrival, utilising 200 enzymes/day Flask Lab capacity and including custom CMO where customers supply their own expression plasmids.
  • Bulk CMO Service Fee-for-service large-scale enzyme manufacturing from 1 kg to 100 kg using Prozomix's 750 L Pilot Plant and 3 × 2400 L Production Plant (6,000 L total), with fixed commoditised pricing and long-term dedicated LOT storage.
  • Prozomix Promise (Hit Improvement Service) Free-of-charge biocatalyst hit improvement service selecting 12–24 homologues from Prozomix's proprietary metagenomic database to optimise enzyme activity, selectivity, or stability; customers with an existing enzyme hit that is not good enough receive homologues synthesised, cloned, and produced free-of-charge for screening.
  • Commercial Academic Partner (CAP) Programme Academic partnership programme enabling rapid commercialisation of recombinant enzymes with a 17.5% royalty paid to the academic contributor on all sales, achieving commercialisation within approximately 3 months.
  • Literature Enzyme Request Service Service that makes published biocatalysts available as off-the-shelf products, paying a 10% gross sales royalty to originating academics and providing 2–4 week delivery for new requests.
  • Immobilised Enzymes (via CLEA Technologies collaboration) Custom enzyme immobilisation services for Prozomix enzymes (KREDs, EREDs, P450s, nitrilases) provided through collaboration with CLEA Technologies B.V., combining GRASP™ biocatalyst development with CLEA's advanced immobilisation technology.
  • CoEBio3 Consortium Products Commercial consortium products including the CoEBio3 P450 Collection and CoEBio3 R-AMO (R-Selective Amine Oxidases) Collection, developed through the Centre of Excellence for Biocatalysis, available at $165.00 per 96-well screening plate (1 mg each enzyme per well).

Quantifiable outcome

  • 17 of the top 20 global pharmaceutical companies use Prozomix
  • +6 more outcomes

Companies that use Prozomix

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Prozomix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature7 records

Prozomix partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • SK pharmtecocoreStrategic or Co-development Partner · 24 March 2026SK pharmteco, a global contract development and manufacturing organization (CDMO), and Prozomix announced a strategic partnership to integrate Prozomix's biocatalyst libraries into SK pharmteco's small-molecule development and manufacturing services. SK pharmteco gains access to over 6,000 diverse native biocatalysts for use across its R&D centers in the U.S., Europe, and Asia, enabling rapid identification of high-performing enzymes for complex active pharmaceutical ingredient synthesis. The partnership aims to accelerate the transition to more sustainable, efficient, and cost-effective pharmaceutical manufacturing processes for clients globally.
  • Meiji Seika Pharma Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 2 April 2012Meiji Seika Pharma Co., LTD. was appointed as Prozomix's exclusive distributor in Japan in April 2012. Meiji hosts a Japanese version of the Prozomix enzyme catalogue on its website, ensuring both good web visibility and efficient customer experience locally in Japan. With their fundamental and applied knowledge of enzyme technology and industrial enzyme capability, this collaboration is an important milestone in Prozomix's global marketing strategy.
  • Ginkgo BioworkscoreTechnology or IntegrationProzomix collaborates with Ginkgo Bioworks to leverage customer screening data from the Biocatalysis Enzyme Toolkit, enabling the development of second generation (Gen2) and next generation (NextGen) AI-powered enzyme solutions. Customers can leverage their historical and new Prozomix screening data in collaboration with Ginkgo to unlock unrivalled AI enzyme solutions for demanding applications.
  • KYROBIO Consortium (EU FP7-KBBE Programme)coreStrategic or Co-development PartnerAs part of a 17-strong academic/commercial EU consortium, Prozomix participated in the €7.8M KYROBIO Project (Grant No. 289646) under the FP7-KBBE Programme, aimed at discovering, developing, and demonstrating biocatalysts for industrial synthesis of chiral chemicals. The consortium included BICT, Ingenza, CLEA Technologies, BioInfoBank Institute, VTU Technology, ACIB, University of Graz, X-Zyme, evocatal, Bio-prodict, University of Manchester, CIKTN, C-Tech Innovation, University of Groningen, University of Stuttgart, and Technical University of Denmark. Prozomix's role was discovery, development, and commercialisation of novel nitrile hydratase biocatalysts.
  • Bluetools Consortium (EU Horizon Europe Programme)coreStrategic or Co-development PartnerAs part of a 14-strong academic/commercial EU consortium, Prozomix was awarded a Horizon Europe research grant (Project Grant No. 101081957) focused on 'Safely and sustainably utilising marine microbiomes'. Over a 4-year period, Prozomix is using its advanced enzyme capabilities to discover, develop, and commercialise novel biocatalysts from UK marine biodiversity, expanding its collection of Biocatalysis enzymes with new members becoming commercially available through the Biocatalysis Enzyme Toolkit.
  • Northumbria UniversityminorStrategic or Co-development PartnerNorthumbria University and Prozomix have collaborated on multiple research projects including a BBSRC iCASE Award (2015) focused on novel biocatalytic routes towards volatile sulphur compounds, and a TSB Grant for sustainable flavour compound production from vegetable oil waste streams.

Scale indicators13 records

Recent moves7 records

Expansion highlights5 records

Prozomix competitors and assessment

Company assessment

Broad incumbents

  • Amano Enzyme: Amano Enzyme is a Japanese specialty enzyme manufacturer with a long-established presence in food, pharmaceutical, and diagnostic enzymes. It is comparable as a broad incumbent in the global enzyme market, with a similar global distribution model and a Japanese home market presence.
  • Biosynth: Biosynth (formerly Biosynth Carbosynth) is a large specialty chemicals and life sciences supplier with a growing enzyme and biocatalysis portfolio. It is comparable as a broad incumbent that supplies life science tools and specialty enzymes to pharmaceutical and academic customers globally.
  • Novonesis (formerly Novozymes): Novonesis is the world's largest industrial enzyme company, offering a broad portfolio across food, beverage, agriculture, and pharma. While not specialising in pharma API biocatalysis, its scale and R&D resources make it a broad incumbent whose moves into biocatalysis could threaten niche players like Prozomix.
  • AB Enzymes (Associated British Foods): AB Enzymes is an established industrial enzyme manufacturer with a broad product portfolio in food, baking, and brewing. It serves as a broad incumbent comparable in the enzyme industry, with significant manufacturing scale and customer relationships.

Emerging players

  • Arzeda: Arzeda combines computational protein design with synthetic biology to create novel enzymes for industrial applications. It is comparable as an emerging player in enzyme engineering, taking a competing AI-first approach to the same pharma and industrial customers.
  • EnginZyme: EnginZyme is a Swedish company developing immobilised enzyme technology for chemical manufacturing. It is comparable as an emerging player in industrial biocatalysis with overlapping pharma and industrial customer use cases, though its focus is on immobilisation rather than enzyme discovery.
  • Bota Bio: Bota Bio is a synthetic biology company developing engineered enzymes and microbes for sustainable chemical and material production. It is comparable as an emerging player in AI-driven enzyme engineering for industrial applications, with overlapping pharmaceutical and specialty chemical customers.

Direct peers

  • Codexis: Codexis is a leading enzyme engineering company focused on biocatalysts for pharmaceutical manufacturing, serving the same big-pharma customer base with both native and engineered enzymes. It is the most direct competitor to Prozomix's Biocatalysis Enzyme Toolkit and CMO services.
  • c-LEcta (Kerry Group): c-LEcta is a German biocatalysis company developing and commercialising engineered enzymes for pharma, food, and industrial applications, now part of Kerry Group. It directly competes with Prozomix in supplying specialty biocatalysts to pharmaceutical manufacturers.
  • Evocatal (acquired by BASF): Evocatal was a German specialty enzyme company focused on biocatalysis for industrial applications, with a comparable product portfolio in oxidoreductases, transaminases, and hydrolases. Acquired by BASF, it represents a direct competitive comparable in the biocatalyst space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Prozomix social profiles

Digital presence

Prozomix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prozomix leadership team

Management profile

Number of profiles

Profiles2 records

Prozomix funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prozomix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prozomix

What does Prozomix do?

Prozomix discovers, manufactures, and supplies highly purified novel enzymes (biocatalysts) for pharmaceutical and industrial biocatalysis. It offers the free Biocatalysis Enzyme Toolkit — over 6,000 native enzymes across 50+ panels — for screening, with hits then purchased at commoditised global prices from 100 mg to 100 kg. The company also provides small-scale and bulk contract manufacturing (CMO) services, AI-optimised Gen2/NextGen enzymes via Ginkgo Bioworks, and academic commercialisation programmes.

Is Prozomix a public or private company?

Prozomix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Prozomix founded?

Prozomix was founded in 2008. It employs 11 to 50 people.

Where is Prozomix based?

Prozomix is headquartered in Haltwhistle, United Kingdom, in the Europe region.

How does Prozomix make money?

Four revenue lines are on record. Enzyme Product Sales are the primary driver. The others are contract Manufacturing (CMO) Services, commercial Academic Partner (CAP) Programme and AI Enzyme Optimisation Services.

Who are Prozomix's main competitors?

Broad incumbents on record are Amano Enzyme, Biosynth, Novonesis (formerly Novozymes) and AB Enzymes (Associated British Foods). Emerging players are Arzeda, EnginZyme and Bota Bio. Direct peers are Codexis, c-LEcta (Kerry Group) and Evocatal (acquired by BASF).

Does Prozomix have an API?

No public API is recorded for Prozomix.

What industry is Prozomix in?

Prozomix's product category is Biocatalysis Enzymes / Industrial Biocatalysts. Its primary akta.pro industry code is EUAAAIAL, Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids), with a secondary code of HLAAAJAI, Bioprocess Consumables & Reagents (resins, membranes, media components, buffers). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Manila TimesSK pharmteco and Prozomix Announce Strategic Collaboration to Enhance Biocatalysis Capabilities for Global Drug ManufacturingSK pharmteco, a global contract development and manufacturing organization (CDMO), and Prozomix, a UK-based biotechnology company specializing in enzyme discovery, announced a strategic partnership to integrate Prozomix’s biocatalyst libraries into SK pharmteco’s small-molecule development and manufacturing services. Through this collaboration, SK pharmteco gains access to over 6,000 diverse native biocatalysts for use across its R&D centers in the U.S., Europe, and Asia, enabling rapid identification of high-performing enzymes for complex active pharmaceutical ingredient synthesis. The partnership aims to accelerate the transition to more sustainable, efficient, and cost-effective pharmaceutical manufacturing processes for clients globally.GlobeNewswireSK pharmteco and Prozomix Announce Strategic Collaboration to Enhance Biocatalysis Capabilities for Global Drug ManufacturingSK pharmteco and Prozomix announced a strategic partnership to integrate Prozomix's biocatalyst libraries into SK pharmteco's small-molecule development and manufacturing services. The collaboration gives SK pharmteco access to over 6,000 native biocatalysts for enzyme screening across its R&D centers. The partnership aims to accelerate sustainable pharmaceutical processes and expand SK pharmteco's technology offerings.NTB KommunikasjonSK pharmteco and Prozomix Announce Strategic Collaboration to Enhance Biocatalysis Capabilities for Global Drug ManufacturingSK pharmteco and Prozomix have announced a strategic partnership to integrate Prozomix's biocatalyst libraries, comprising over 6,000 diverse enzymes, into SK pharmteco's global small-molecule development and manufacturing services across the U.S., Europe, and Asia. The collaboration aims to accelerate the adoption of sustainable, enzyme-based synthesis methods for complex active pharmaceutical ingredient (API) manufacturing, offering clients a streamlined path from enzyme screening to commercial-scale production. The deal expands SK pharmteco's technology offerings as a multi-modality CDMO partner while providing Prozomix access to a broader spectrum of high-value pharmaceutical projects through SK pharmteco's worldwide manufacturing network.BioSpaceSK pharmteco and Prozomix Announce Strategic Collaboration to Enhance Biocatalysis Capabilities for Global Drug ManufacturingSK pharmteco and Prozomix announced a strategic partnership to integrate Prozomix's biocatalyst libraries into SK pharmteco's small-molecule development and manufacturing services. Through this collaboration, SK pharmteco gains access to over 6,000 diverse native biocatalysts to screen across its R&D centers in the U.S., Europe, and Asia, enabling rapid identification of high-performing enzymes for complex Active Pharmaceutical Ingredient synthesis. The partnership aims to accelerate the transition to sustainable, enzyme-based pharmaceutical manufacturing as drug molecules become increasingly complex.YahooPrecision Fermentation Market Trends, Opportunities, and Forecasts, 2020-2024 & 2025-2030 - Market is Expanding Beyond Food and Beverage Into Pharmaceuticals, Cosmetics, and Industrial EnzymesResearchAndMarkets.com has published a global industry report forecasting the precision fermentation market to grow from USD 589.46 million in 2024 to USD 3.27 billion by 2030, driven by demand for sustainable proteins and advancements in genetic engineering. The report highlights diversification into pharmaceuticals and cosmetics, citing collaborations such as those between Prozomix and Ginkgo Bioworks, while noting scaling challenges as a key barrier to growth.PR NewswireAI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029A Mordor Intelligence research report projects the artificial intelligence in healthcare market to grow at a compound annual growth rate of 42.20% through 2029. Several companies are actively developing AI healthcare solutions, including Avant Technologies Inc., which acquired Wired-4-Health to strengthen its AI-powered healthcare offerings and support its goal of building the first supercomputing network in the country. Additional active participants include Microsoft (expanding Azure AI Health Bot services with healthcare safeguards), Health Catalyst (partnering with SacValley MedShare), Ginkgo Bioworks (acquiring Reverie Labs assets and partnering with UK-based Prozomix), and Recursion Pharmaceuticals (launching a new drug discovery platform and collaborating with Nvidia).Investing.comGinkgo Bioworks and Prozomix partner for enzyme innovation in API productionProzomix and Ginkgo Bioworks announced a partnership to develop enzymes for active pharmaceutical ingredient manufacturing, combining Ginkgo's AI/ML with Prozomix's enzyme data. The collaboration will create new enzyme plates for pharmaceutical process chemistry groups, with screening data shared to refine Ginkgo's models.PR NewswireProzomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API ManufacturingProzomix and Ginkgo Bioworks announced a partnership to develop next-generation enzyme plates for API manufacturing, combining Ginkgo's AI/ML models with Prozomix's enzyme libraries. The collaboration aims to create more diverse and performant biocatalysts, with plates freely available to pharma process chemistry groups in exchange for screening data.